Published in Mol Neurobiol on April 15, 2014
Adeno-associated virus-mediated cancer gene therapy: current status. Cancer Lett (2014) 0.80
Specific amyloid β clearance by a catalytic antibody construct. J Biol Chem (2015) 0.76
Intracranial delivery of interleukin-17A via adeno-associated virus fails to induce physical and learning disabilities and neuroinflammation in mice but improves glucose metabolism through AKT signaling pathway. Brain Behav Immun (2015) 0.75
Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications. J Biomed Res (2016) 0.75
Intracranial IL-17A overexpression decreases cerebral amyloid angiopathy by upregulation of ABCA1 in an animal model of Alzheimer's disease. Brain Behav Immun (2017) 0.75
Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene (1991) 38.64
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol (2008) 6.82
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods (2002) 5.30
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science (2002) 3.93
Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther (2009) 3.33
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol (2004) 3.01
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther (2006) 2.67
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology (2005) 2.58
Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther (2003) 2.49
Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci (2009) 2.33
Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol (2013) 2.29
Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci (2005) 2.21
Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem (2002) 2.13
Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med (2002) 2.12
Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci (2008) 1.98
Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther (2003) 1.94
A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci (2007) 1.91
Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther (2011) 1.79
Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis (2004) 1.73
Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol (2002) 1.68
Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol (2009) 1.65
Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci (2004) 1.65
Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides (2002) 1.64
Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther (2013) 1.52
Nerve inflammation halts trial for Alzheimer's drug. Nature (2002) 1.44
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 1.39
An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci (2012) 1.36
Microglia during development and aging. Pharmacol Ther (2013) 1.30
Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci (2000) 1.27
Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging (2004) 1.22
Alzheimer's drugs take a new tack. Nature (2012) 1.20
Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Expert Opin Biol Ther (2013) 1.12
Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. Gene Ther (2011) 1.09
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun Ageing (2013) 1.08
Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther (2009) 1.07
Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis (2006) 1.04
Site-directed mutagenesis of proteolytic antibody light chain. J Mol Biol (1995) 1.03
Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. Mol Ther (2011) 0.98
Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model. Biochem Biophys Res Commun (2006) 0.95
A safer vaccine for Alzheimer's disease? Neurobiol Aging (2002) 0.93
Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization. Biochem J (2000) 0.93
Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci Rep (2013) 0.93
Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. J Biol Chem (2008) 0.90
Amyloid double trouble. Nat Genet (2006) 0.87
Crystal structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural proteolytic antibody. Biochem J (2006) 0.87
Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model. J Alzheimers Dis (2011) 0.86
Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. PLoS One (2013) 0.86
Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun Rev (2008) 0.84
Urokinase-type plasminogen activator inhibits amyloid-beta neurotoxicity and fibrillogenesis via plasminogen. J Neurosci Res (2002) 0.83
Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease. J Neuroimmunol (2012) 0.76
Bias-corrected maximum likelihood estimator of the negative binomial dispersion parameter. Biometrics (2005) 4.06
Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat Med (2006) 2.11
Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2008) 1.67
Strand transfer events during HIV-1 reverse transcription. Virus Res (2008) 1.51
Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics (2008) 1.51
Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis. J Gastroenterol Hepatol (2009) 1.50
Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol (2004) 1.37
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res (2011) 1.35
Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab Dispos (2009) 1.34
c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J Immunol (2004) 1.30
The application of Fe3O4 nanoparticles in cancer research: a new strategy to inhibit drug resistance. J Biomed Mater Res A (2007) 1.27
Mimecan/osteoglycin-deficient mice have collagen fibril abnormalities. Mol Vis (2002) 1.27
TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflammation (2011) 1.26
First prospective, population-based inflammatory bowel disease incidence study in mainland of China: the emergence of "western" disease. Inflamm Bowel Dis (2013) 1.25
Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl (2013) 1.21
Accumulation of protein O-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high O-GlcNAc metabolism. J Neurochem (2004) 1.20
Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol (2006) 1.19
Capture and stimulated release of circulating tumor cells on polymer-grafted silicon nanostructures. Adv Mater (2012) 1.16
High-purity prostate circulating tumor cell isolation by a polymer nanofiber-embedded microchip for whole exome sequencing. Adv Mater (2013) 1.16
Synergistic enhancement effect of magnetic nanoparticles on anticancer drug accumulation in cancer cells. Nanotechnology (2006) 1.13
Specific capture and release of circulating tumor cells using aptamer-modified nanosubstrates. Adv Mater (2013) 1.13
Alternative splicing of Slo channel gene programmed by estrogen, progesterone and pregnancy. FEBS Lett (2005) 1.08
Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. BMC Mol Biol (2012) 1.08
Ontogeny of proteolytic immunity: IgM serine proteases. J Biol Chem (2004) 1.07
Modulation of alpha and beta crystallin expression in rat retinas with ocular hypertension-induced ganglion cell degeneration. Brain Res (2007) 1.06
NanoVelcro Chip for CTC enumeration in prostate cancer patients. Methods (2013) 1.05
Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol (2003) 1.04
A comparison study on algorithms of detecting long forms for short forms in biomedical text. BMC Bioinformatics (2007) 1.01
Aging, ion channel expression, and vascular function. Vascul Pharmacol (2002) 1.01
Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. J Biol Chem (2004) 1.01
Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem (2003) 1.01
Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem (2007) 1.00
Building the process-drug-side effect network to discover the relationship between biological processes and side effects. BMC Bioinformatics (2011) 1.00
Akt activation is responsible for enhanced migratory and invasive behavior of arsenic-transformed human bronchial epithelial cells. Environ Health Perspect (2011) 1.00
Entitymetrics: measuring the impact of entities. PLoS One (2013) 1.00
Expression and regulation mechanisms of Sonic Hedgehog in breast cancer. Cancer Sci (2010) 0.99
Gene expression changes in the retina following optic nerve transection. Mol Vis (2006) 0.99
Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection. AIDS Res Hum Retroviruses (2007) 0.98
The enhancement effect of gold nanoparticles in drug delivery and as biomarkers of drug-resistant cancer cells. ChemMedChem (2007) 0.98
Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen) can be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine. Drug Metab Dispos (2008) 0.98
Noggin and BMP4 co-modulate adult hippocampal neurogenesis in the APP(swe)/PS1(DeltaE9) transgenic mouse model of Alzheimer's disease. Biochem Biophys Res Commun (2009) 0.96
Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond. Alcohol (2009) 0.96
Tissue-specific regulation of Ca(2+) channel protein expression by sex hormones. Biochim Biophys Acta (2002) 0.94
MyD88 deficiency ameliorates β-amyloidosis in an animal model of Alzheimer's disease. Am J Pathol (2011) 0.93
Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase. Acta Pharmacol Sin (2010) 0.93
Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. AIDS (2004) 0.92
Green tea epigallocatechin-3-gallate (EGCG) promotes neural progenitor cell proliferation and sonic hedgehog pathway activation during adult hippocampal neurogenesis. Mol Nutr Food Res (2012) 0.92
A jacalin-related lectin-like gene in wheat is a component of the plant defence system. J Exp Bot (2011) 0.91
Clinical and biological significance of never in mitosis gene A-related kinase 6 (NEK6) expression in hepatic cell cancer. Pathol Oncol Res (2011) 0.90
Peripheral nerve lesion induces an up-regulation of Spy1 in rat spinal cord. Cell Mol Neurobiol (2008) 0.90
Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. J Biol Chem (2008) 0.90
Expression of hermes gene is restricted to the ganglion cells in the retina. Neurosci Lett (2006) 0.90
Combinatorial metabolism notably affects human systemic exposure to ginsenosides from orally administered extract of Panax notoginseng roots (Sanqi). Drug Metab Dispos (2013) 0.89
Tumor necrosis factor-alpha inhibits Schwann cell proliferation by up-regulating Src-suppressed protein kinase C substrate expression. J Neurochem (2009) 0.89
Differential signaling of T cell generation of IL-4 by wild-type and short-deletion variant of type 2 G protein-coupled receptor for vasoactive intestinal peptide (VPAC2). J Immunol (2006) 0.89
Antibodies as defensive enzymes. Springer Semin Immunopathol (2005) 0.89
Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. AIDS (2010) 0.89
Catalytic antibodies to HIV: physiological role and potential clinical utility. Autoimmun Rev (2008) 0.88
Naturally occurring catalytic antibodies: evidence for preferred development of the catalytic function in IgA class antibodies. Mol Biotechnol (2007) 0.88
Towards irreversible HIV inactivation: stable gp120 binding by nucleophilic antibodies. J Mol Recognit (2006) 0.87
Broadly distributed nucleophilic reactivity of proteins coordinated with specific ligand binding activity. J Mol Recognit (2005) 0.87
Carbendazim induces a temporary change in soil bacterial community structure. J Environ Sci (China) (2009) 0.87
SIAH1 induced apoptosis by activation of the JNK pathway and inhibited invasion by inactivation of the ERK pathway in breast cancer cells. Cancer Sci (2009) 0.87
The expression of SIAH1 is downregulated and associated with Bim and apoptosis in human breast cancer tissues and cells. Mol Carcinog (2010) 0.87
Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF. Vaccine (2005) 0.86
Theory of proteolytic antibody occurrence. Immunol Lett (2005) 0.86
Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model. J Alzheimers Dis (2011) 0.86
Towards covalent vaccination: improved polyclonal HIV neutralizing antibody response induced by an electrophilic gp120 V3 peptide analog. J Biol Chem (2007) 0.86
Neurologic and motor dysfunctions in APP transgenic mice. Rev Neurosci (2012) 0.85
Antibodies to the superantigenic site of HIV-1 gp120: hydrolytic and binding activities of the light chain subunit. Mol Immunol (2007) 0.85
Detecting duplicate biological entities using Shortest Path Edit Distance. Int J Data Min Bioinform (2010) 0.85
Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine. J Immunol (2012) 0.84
Glucocorticoids facilitate astrocytic amyloid-β peptide deposition by increasing the expression of APP and BACE1 and decreasing the expression of amyloid-β-degrading proteases. Endocrinology (2011) 0.84
Kv channels contribute to nitric oxide- and atrial natriuretic peptide-induced relaxation of a rat conduit artery. J Pharmacol Exp Ther (2006) 0.84
PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China. Acta Pharmacol Sin (2012) 0.84
VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease. FASEB J (2003) 0.84
Constant domain-regulated antibody catalysis. J Biol Chem (2012) 0.84
Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun Rev (2008) 0.84
The expression of tumor necrosis factor-alpha (TNF-alpha) by the intrathecal injection of lipopolysaccharide in the rat spinal cord. Neurochem Res (2008) 0.84
Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J Biol Chem (2009) 0.83
Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA. Tumour Biol (2010) 0.83
Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide. J Clin Immunol (2010) 0.83